Prostate cancer is the most common cancer in men and is second most common cause of cancer deaths. Importantly, the annual rates of prostate cancer incidence continue to rise. This session will delve ...

Prostate cancer stands as a prevalent threat to men's health, ranking second in cancer-related deaths in the United States. Each year, approximately 250,000 men in the U.S. receive a prostate cancer ...

Benefits include better discrimination between risk levels. (HealthDay News) — Patient-centered pathology reports (PCPR) help patients to understand prostate cancer results better than current ...

Individual patient data (IPD) analysis of early PSA nadir in ARASENS, LATITUDE, and TITAN: Training and validation of a novel model. Assessing genomic instability (GI) by shallow whole-genome ...

Pathologic concordance between prostate biopsy and radical prostatectomy improves with use of a novel robotic-assisted transperineal fusion biopsy platform. Optimization of risk stratification at ...

HNL Lab Medicine is the laboratory partner affiliated with Lehigh Valley Health Network, part of Jefferson Health, which includes 14 hospital campuses and 981 licensed acute beds across its flagship ...

SAN FRANCISCO--(BUSINESS WIRE)--Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, announced today that the U.S. Food and Drug ...

Human tissue is intricate, complex and, of course, three dimensional. But the thin slices of tissue that pathologists most often use to diagnose disease are two dimensional, offering only a limited ...

If you’ve recently been diagnosed with prostate cancer, or if you’ve had a prostate biopsy to test for prostate cancer, you might have seen the term “Gleason score” or “Gleason grade” on the pathology ...

Prognostic implications of PSA levels at 7 months in metastatic hormone-sensitive prostate cancer treated with enzalutamide: Landmark analysis of ENZAMET (ANZUP 1304). This is an ASCO Meeting Abstract ...